Skip to main content
Premium Trial:

Request an Annual Quote

Mustang Bio Reports Positive Phase I/II Data for CD20-Targeted CAR T-Cell Therapy

NEW YORK – Mustang Bio on Monday said 90 percent of patients with Waldenstrom macroglobulinemia responded to treatment with its CD20-targeted autologous CAR T-cell therapy MB-106 in an ongoing Phase I/II trial.

In the trial, Mustang investigators are evaluating the safety, tolerability, and efficacy of MB-106 in patients with a range of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphoid leukemias, including Waldenstrom macroglobulinemia. To be eligible for the trial, patients must have evidence of CD20 expression. As the primary efficacy endpoint, investigators are tracking patients' objective response rate after 24 months of the trial and, as secondary efficacy endpoints, are following progression-free survival, overall survival, minimal residual disease, and duration of response.

The Worcester, Massachusetts-based company enrolled 10 patients with Waldenstrom macroglobulinemia in the trial, all of whom had progressed on a Bruton's tyrosine kinase inhibitor. Nine out of the 10 patients responded to treatment. Three had complete responses, six had partial responses, and one had stable disease. Among those who had a complete response, one patient remained in remission for 31 months.

Nine patients had grade 1 or 2 cytokine release syndrome, and one had grade 1 immune effector cell-associated neurotoxicity syndrome.

Another Phase I/II clinical trial of MB-106 is underway at Fred Hutchinson Cancer Center in which patients with follicular lymphoma treated with MB-106 had an 80 percent complete response rate and, among six patients with Waldenstrom macroglobulinemia, two had a complete response.

In March, Mustang announced plans to expand clinical development of MB-106 into autoimmune disease, and the company is also developing a MB-109, combination CAR T-cell and oncolytic virus therapy, as a treatment for IL13Rα2-expressing glioblastoma and astrocytoma.